(BUSINESS WIRE) – Illumina, Inc. today announced that Dr. Frances Arnold has joined the company’s Board of Directors. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Dr. Arnold joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor and Director. Her laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals and medicine.
“We are very pleased to welcome Dr. Arnold to our board and look forward to leveraging her experience and expertise in life sciences and medicine,” said Jay Flatley, Illumina Chief Executive Officer. “We value the perspective and passion that she will bring to the role as we plan for growth in our clinical and research markets.”
Dr. Arnold is the recipient of numerous honors, including induction into the National Inventors Hall of Fame (2014), Fellow of the National Academy of Inventors (2014), the ENI Prize in Renewable and Nonconventional Energy (2013), the US National Medal of Technology and Innovation (2011), and the Charles Stark Draper Prize of the US National Academy of Engineering (2011). She has been elected to membership in all three US National Academies, of Science, Medicine, and Engineering and the American Academy of Arts and Sciences.
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.